Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 2/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4167072 | 0.81 | CAPN1 (0.36) | PPARASCDHCAR2 | |
| SCHEMBL2528074 | 0.81 | PPARA (0.40) | PPARAHCAR2MAPT | |
| SCHEMBL30314694 | 0.77 | HCAR2 (0.36) | PPARASCDCHRNB2CHRNA4HCAR2 | |
| SCHEMBL12467073 | 0.77 | EPHX2 (0.40) | SCDHCAR2 | |
| SCHEMBL15273772 | 0.77 | SCD (0.36) | SCDHCAR2 | |
| SCHEMBL25180195 | 0.72 | LMNA (0.36) | SCDCHRNA4HCAR2 | |
| SCHEMBL30043569 | 0.72 | POLB (0.41) | SCDHCAR2 | |
| SCHEMBL15289890 | 0.72 | KLKB1 (0.38) | SCDHCAR2 | |
| SCHEMBL4146016 | 0.71 | PPARA (0.41) | PPARACHRNB2CHRNA4 | |
| SCHEMBL15964809 | 0.71 | NR3C2 (0.48) | CA2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131483-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | HANSEN PETER | 2009-05-21 | — | — | US | disclosed |
| EP-1861370-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006098683-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131483-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | SERPINB1, ELANE, MPO | PPARA 3705/4885SCD 3955/4885CHRNB2 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.